文献速递糖尿病

NT-proBNP改善2型糖尿病心肾并发症预测:香港糖尿病生物样本库

NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes: the Hong Kong Diabetes Biobank.
PubMed 文献 · Diabetologia · 2024-11-07

在香港糖尿病生物样本库的多中心前瞻性队列中测量1993份样本的NT-proBNP,以≥125 pg/ml定义升高。24.7%的参与者NT-proBNP升高,校正年龄、性别和糖尿病病程后与房颤、冠心病、心血管疾病和充血性心力衰竭发生风险显著相关,含NT-proBNP的模型预测能力优于已有临床风险模型。

要点

  • 24.7%的参与者NT-proBNP≥125 pg/ml,其基线心肾并发症频率高2-4倍。
  • NT-proBNP升高与房颤、冠心病、心血管疾病和充血性心力衰竭发生风险显著相关。
  • 含NT-proBNP的模型对多种心肾终点预测能力优于已有临床风险模型。

核心结论

  • NT-proBNP在2型糖尿病中展现出作为多种心肾并发症预后标志物的潜力。
  • 在临床评估中考虑NT-proBNP可能有助于识别可从更强化治疗中获益的高危个体。

研究设计与样本

  • 香港糖尿病生物样本库是多中心前瞻性糖尿病队列与生物样本库,共测量1993份样本的NT-proBNP。
  • 以≥125 pg/ml为切点定义NT-proBNP升高。
  • 采用Cox回归分析NT-proBNP升高与新发心血管和肾脏终点的关联,校正性别、年龄、糖尿病病程及其他协变量。
  • 采用一致性指数(C指数)、净重分类改善指数、综合判别改善指数和相对综合判别改善指数评估NT-proBNP相较于亚洲糖尿病联合评估(JADE)风险方程对冠心病、充血性心力衰竭和肾衰竭的预测价值。

主要发现

  • 24.7%的参与者NT-proBNP升高,其基线心肾并发症频率高2-4倍且心脏代谢谱更差。
  • 校正基线年龄、性别和糖尿病病程后,NT-proBNP升高与新发房颤(HR 4.64 [95% CI 2.44, 8.85])、冠心病(HR 4.21 [2.46, 7.21])、心血管疾病(HR 3.32 [2.20, 5.01])和充血性心力衰竭(HR 4.18 [2.18, 8.03];所有p<0.001)相关。
  • 进一步校正其他协变量后上述关联仍显著。
  • NT-proBNP升高对多种心肾终点有良好判别能力:冠心病C指数0.83(95% CI 0.76, 0.90),房颤C指数0.88(0.81, 0.94),充血性心力衰竭C指数0.89(0.83, 0.95),eGFR下降40% C指数0.81(0.77, 0.84),肾衰竭C指数0.88(0.84, 0.92)。
  • 含NT-proBNP的模型预测能力优于已有临床风险模型。

关键数值与推荐

  • NT-proBNP升高定义为≥125 pg/ml。
  • NT-proBNP升高与新发房颤风险的HR为4.64(95% CI 2.44, 8.85)。
  • NT-proBNP升高与新发冠心病风险的HR为4.21(95% CI 2.46, 7.21)。
  • NT-proBNP升高与新发心血管疾病风险的HR为3.32(95% CI 2.20, 5.01)。
  • NT-proBNP升高与新发充血性心力衰竭风险的HR为4.18(95% CI 2.18, 8.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: N-terminal pro B-type natriuretic peptide (NT-proBNP) is a natriuretic peptide that is strongly associated with congestive heart failure (CHF). The utility of NT-proBNP for prediction of cardiovascular events and renal endpoints, compared with clinical risk factors, has not been evaluated in detail. We hypothesise that NT-proBNP can improve risk stratification and prediction of cardiorenal events in type 2 diabetes, beyond that provided by clinical risk factors. METHODS: NT-proBNP was measured in 1993 samples from the Hong Kong Diabetes Biobank, a multicentre prospective diabetes cohort and biobank. A cut-off of ≥125 pg/ml was used to define elevated NT-proBNP. Associations between elevated NT-proBNP and incident cardiovascular and renal endpoints were examined using Cox regression, adjusted for sex, age and duration of diabetes, as well as other covariates. Prognostic and incremental predictive values of NT-proBNP in diabetes cardiorenal complications, compared with those of the Joint Asia Diabetes Evaluation risk equations for CHD, CHF and kidney failure, were evaluated using the concordance index (C index), net reclassification improvement index, integrated discrimination improvement index and relative integrated discrimination improvement index. RESULTS: A total of 24.7% of participants had elevated NT-proBNP. Participants with elevated NT-proBNP at baseline had a more adverse cardiometabolic profile, with 2-4-fold higher frequency of complications at baseline. Adjusting for age at baseline, sex and duration of diabetes, elevated NT-proBNP was associated with incident atrial fibrillation (HR 4.64 [95% CI 2.44, 8.85]), CHD (HR 4.21 [2.46, 7.21]), CVD (HR 3.32 [2.20, 5.01]) and CHF (HR 4.18 [2.18, 8.03]; all p<0.001). All these associations remained significant after further adjustment for additional covariates. Elevated NT-proBNP had good discriminative ability for various cardiorenal endpoints, with C index of 0.83 (95% CI 0.76, 0.90) for CHD, 0.88 (0.81, 0.94) for atrial fibrillation, 0.89 (0.83, 0.95) for CHF, 0.81 (0.77, 0.84) for 40% drop in eGFR and 0.88 (0.84, 0.92) for kidney failure. Models incorporating NT-proBNP had improved prediction compared with established clinical risk models. Sensitivity analyses including alternative cut-off of NT-proBNP, as well as use of other risk engines of CHD, yielded similar results. CONCLUSIONS/INTERPRETATION: NT-proBNP demonstrated a promising ability to serve as a prognostic marker for a variety of cardiorenal complications in type 2 diabetes. Considering NT-proBNP in clinical assessments could potentially help identify high-risk individuals who may benefit from more intensive therapies.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Ma RCW, Tam CHT, Hou Y, et al. NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes: the Hong Kong Diabetes Biobank. Diabetologia. 2024. PMID: 39508878. doi:10.1007/s00125-024-06299-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。